In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
Efficacy and Safety of Levetiracetam for the Prevention of Alcohol Relapse in Recently Detoxified Alcohol-Dependent Patients: A Randomized Trial
Background Antiepileptics have been shown to reduce alcohol intake or to prevent relapse in patients with alcoholism . Goal To investigate if the new antiepileptic levetiracetam ( LEV ) prevents relapse after detoxification compared with placebo in patients with alcohol dependence . Methods Two hundred one patients were included in the prospect i ve , r and omized , double-blind , multicenter , placebo-controlled trial . After detoxification treatment and a screening period of 7 days , patients were r and omized to treatment with LEV or placebo . Medication was administered in a fixed-dose schedule for 16 weeks . Primary outcome parameters were the overall rate and time to relapse with heavy drinking . Secondary outcome parameters were time to the first drink , craving , adherence , tolerability , and safety data ( mean corpuscular volume , serum alanine aminotransferase , serum aspartate aminotransferase , & ggr;-glutamyltransferase ) . Results The rate of relapse and the time to relapse did not differ significantly between both groups , but less patients treated with LEV terminated treatment early compared with patients receiving placebo .  Tolerability and safety data were similar in the LEV group compared with placebo . Conclusions Our data do not support a significant effect of LEV on relapse prevention in patients with alcohol dependence during the first 16 weeks of abstinence
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .